DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Network-Based Drug Optimization toward the Treatment of Parkinson’s Disease: NRF2, MAO-B, Oxidative Stress, and Chronic Neuroinflammation
Parkinson’s disease (PD), the second most common neurodegenerative disorder, affects around 10 million people worldwide. It is a multifactorial disease marked by dopaminergic neuron loss with oxidative stress (OS) and neuroinflammation as key pathological drivers. Current treatments focus on dopamine replacement and are symptomatic, underscoring the urgent need for disease-modifying therapies. Here, we present a novel class of dual MAO-B inhibitors and NRF2 inducers with neuroprotective properties in in vitro PD models. Through an optimization program, we enhanced their MAO-B inhibitory potency, selectivity, and NRF2 induction capacity while achieving favorable pharmacokinetic profiles. Virtual library screening identified two core derivatives, leading to the development of compound 11, which exhibited potent anti-inflammatory and neuroprotective activity in OS-related in vitro models. Compound 11 also demonstrated high liver microsomal stability and favorable pharmacokinetics in mice, making it a promising candidate for further investigation as a potential PD therapy., We are grateful for financial support from the Spanish Ministry
of Health (Instituto de Salud Carlos III) (grant PI17/001700
and PI20/00433), the Spanish Ministry of Science (grant
PID2021-123481OB-I00 to RL and PID2021-124983OB-I00) to JCM), and Comunidad de Madrid (grant P2022/BMD-7230-CAM-22 to RL). P.D. and F.J.S. thank MEC for FPU
fellowships and E.C. thanks ISCIII for PFIS fellowship. The
authors acknowledge the support from the European COST
Action CA20121: Bench to bedside transition for the
pharmacological regulation of NRF2 in noncommunicable
diseases (BenBedPhar). Webpage: https://benbedphar.org/
about-benbedphar. The authors acknowledge technical support
from Tomas Robredo with liver microsome experiments. We
would also like to thank “Fundación Teófilo Hernando” for its
continued support., Peer reviewed